All News

The NBA is giving players the option to invest in the cannabis industry under a new deal.

Our 2023 Portland show features interactive off-site event at ChemHistory, Oregon’s premier compliance laboratory, in an immersive full day experience prior to conference.

Saint Louis University’s (St. Louis, Missouri), Cannabis Science and Operations program received the 2023 Outstanding Program by the University Professional and Continuing Education Association (UPCEA).

Oregon Psilocybin Services (OPS) issued first psilocybin manufacturer license since accepting applications earlier this year.

Read an interview from Pharmaceutical Technology Europe exploring how the European bio/pharma industry’s high regulatory standards and GMP requirements are set to position the region as a frontrunner for pharmaceutical grade manufacturing of cannabis-based medicines.

Initial findings from a recent study suggested that cannabidiol (CBD) derivatives made naloxone treatment more effective, even against the opioid fentanyl.

The study will examine consumption and health of the participants after purchasing selected cannabis products from controlled cultivation under regulated conditions.

In late March, the Wine & Spirits Wholesalers of America submitted a letter to congressional leadership expressing its support for cannabis legalization that uses regulatory frameworks similar to those of the alcohol industry.

Health and safety notices were issued in two states due to concerns about contamination exposure.

Leaf 411 and Mission Dispensaries look to advance cannabis education through their recent membership.

The owner and two biologists at Royal Queen Seeds recently presented their F1 hybrid process and strains in Barcelona, Spain.

A pioneer in global cannabis research, Professor Raphael Mechoulam died March 9th, 2023 in Israel at the age of 92.

The 2023 Portland show will include four tracks–analytical science, medical cannabis, cultivation, psychedelics–plus a discussion on medical cannabis for veterans, and more!

In early March 2023, the US Justice Department launched an online application for individuals who were pardoned for simple possession of cannabis under President Biden's October 6, 2022 proclamation. Applicants can now receive a certificate of proof of their pardon.

A civil lawsuit filed in Arkansas by a medical cannabis patient alleges that three cannabis growers and one testing laboratory inflated the amount of tetrahydrocannabinol (THC) in numerous cannabis products.

In early 2023, Yale School of Medicine announced the foundation of a new center for cannabis research. The center’s inaugural director recently provided commentary on the goals and direction of the research.

Recently, the University of Oxford began an international study to examine the potential therapeutic benefits of cannabidiol (CBD) in treating psychosis or psychotic symptoms.

On February 13, 2023, the US Drug Enforcement Administration (DEA) declared in a letter that the cannabinoids delta-8 and -9 THCO are both considered controlled substances due to their chemical structures.

The House and Senate introduced a revised bill to mandate Veterans Affairs (VA) to conduct research on the effects of medical cannabis on veterans with post-traumatic stress disorder (PTSD) and chronic pain.

Cannabidiol (CBD) was recently studied in Mexico as a treatment for traumatic brain injury and Parkinson’s Disease.

Next month the University of Connecticut (UConn) will hold a two-day cannabis symposium covering a wide variety of topics.

Starting July 1, 2023, Australia will allow the use of psilocybin and 3,4-Methylenedioxymethamphetamine (MDMA) for therapeutic use in a medical setting to treat mental health conditions.

In response to a call for comment on the proposed New York Office of Cannabis Management symbol, the Doctors for Cannabis Regulation submitted a letter outlining the design flaws of the proposed symbol and recommended adopting the International Intoxicating Cannabinoid Product Symbol instead.

A statement released on Thursday, January 26, 2023 from Dr. Janet Woodcock, the principal deputy commissioner of the Food and Drug Administration (FDA), announced that the FDA will work with Congress in formulating regulatory oversight to balance risk and access for products in the cannabidiol (CBD) market.

As access to edible cannabis increases for adults across the United States, children are also becoming more exposed as well.

Results from recently published survey studies on the effect of psilocybin and bipolar disorder offered support for the design of future clinical trials.

This 1 CME credit article evaluates evidence-based behavioral treatments, medications, and management strategies for cannabis use disorder.

A study published in January 2023 examined the effects of high and low doses of cannabigerol (CBG) on mice liver.